ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix

GENEVA, Switzerland, Oct. 13 (Korea Bizwire) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health today announced a strategic relationship with Syneos Health® (Nasdaq:SYHN), the only fully integrated biopharmaceutical solutions organization, to commercialize linzagolix. Linzagolix has the potential to be a best-in-class GnRH receptor antagonist for the treatment of uterine fibroids due [...]